BioMarin Pharma (BMRN) Tops Q2 EPS by 12c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $63.37 --0%
EPS Growth %: +1,008.3%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
NEOV, MANU, CTAS, More
EPS Growth %: +1,008.3%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
NEOV, MANU, CTAS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.15, $0.12 better than the analyst estimate of $0.03. Revenue for the quarter came in at $533.8 million versus the consensus estimate of $520.35 million.
GUIDANCE:
BioMarin Pharma sees FY2022 revenue of $2.06-2.16 billion, versus the consensus of $2.11 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
- Franklin BSP Realty Trust (FBRT) Reiterated at Market Outperform by Citizens
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
